236 results on '"Surinach, Andy"'
Search Results
2. The impact of classic Hodgkin lymphoma on informal caregivers: results from the CONNECT cross-sectional survey
3. Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Stage III or IV Classic Hodgkin Lymphoma Treated With Frontline ABVD: A Retrospective Database Review in the United States
4. Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States
5. Patient preferences in the treatment of stage III/IV classic Hodgkin lymphoma: Results from the CONNECT cross‐sectional survey
6. Burden and cost of comorbidities in patients with neuromyelitis optica spectrum disorder
7. The costs of care from a US claims database in patients with neuromyelitis optica spectrum disorder
8. Use of Patient Health Records to Quantify Drug-Related Pro-arrhythmic Risk
9. 922. Cost-effectiveness of baloxavir marboxil versus oseltamivir or no treatment for the management of influenza in the United States
10. Estimated Effectiveness of Coadministration of the BNT162b2 BA.4/5 COVID-19 Vaccine With Influenza Vaccine
11. Physician frontline treatment preferences for stage III/IV classic Hodgkin lymphoma: the real-world US CONNECT study.
12. Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-cell Lymphoma in the United States
13. Physician frontline treatment preferences for stage III/IV classic Hodgkin lymphoma: the real-world US CONNECT study
14. Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States
15. Observations of Oncologists on Treatment Selection With Interim Positron Emission Tomography–Adapted Approaches in Classic Hodgkin Lymphoma: The Real-World CONNECT Study
16. Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma
17. Cervical cancer geographical burden analyzer: An interactive, open-access tool for understanding geographical disease burden in patients with recurrent or metastatic cervical cancer
18. “Real-world” outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma
19. Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database
20. WITHDRAWN: Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis
21. Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis
22. Real-World Patient Characteristics, Treatment Patterns, and Outcomes in Patients with Stage III/IV Classic Hodgkin Lymphoma Treated with Frontline ABVD: A Retrospective Analysis Using a Real-World Database
23. Real-World Treatment Patterns and Clinical Outcomes with Brentuximab Vedotin or Other Standard Therapies in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): A Retrospective Chart Review Study in the United States
24. Economic Burden of Hematopoietic Cell Transplantation (HCT) Among Commercially Insured Patients with Hematological Malignancies in the United States (US)
25. Health care resource utilization and costs among individuals with vs without Huntington disease in a US population
26. Use of the Postacute Sequelae of COVID-19 Diagnosis Code in Routine Clinical Practice in the US
27. Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy.
28. Cancer-of-Unknown-Primary-Origin: A SEER–Medicare Study of Patterns of Care and Outcomes among Elderly Patients in Clinical Practice
29. Healthcare resource utilization and costs in individuals with Huntington’s disease by disease stage in a US population
30. Cervical cancer geographical burden analyzer: An interactive, open-access tool for understanding geographical disease burden in patients with recurrent or metastatic cervical cancer.
31. The impact of classic Hodgkin lymphoma (cHL) on informal caregivers: Results from the cHL—Real-world observations from physicians, patients, and caregivers on the disease and its treatment (CONNECT) study.
32. Real-world outcomes among patients with HER2+ metastatic breast cancer with brain metastases
33. Patient characteristics and outcomes associated with small cell lung cancer by treatment status in a U.S. Medicare population.
34. The Current Landscape and Emerging Applications for Real‐World Data in Diagnostics and Clinical Decision Support and its Impact on Regulatory Decision Making
35. Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma
36. Impact of the COVID-19 Pandemic on Management of Patients with Metastatic Pancreatic Ductal Adenocarcinoma in the United States
37. Real-world Impact of Age at Diagnosis on Treatment Patterns and Survival Outcomes of Patients with Metastatic Pancreatic Ductal Adenocarcinoma
38. Trends in treatment patterns and costs of care among patients with advanced stage cervical cancer
39. Understanding extended duration of therapy (DOT) among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens.
40. Real-world clinical outcomes of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens: Impact of prior irinotecan (IRI) exposure.
41. Real‐world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma
42. Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Physician First-Line Treatment Preferences for Stage III or IV Classical Hodgkin Lymphoma
43. Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT)-a Cross-Sectional Survey of Patients with Stage III or IV Classical Hodgkin Lymphoma Compared By Age
44. Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Observations of Physicians on Treatment and Interim PET-Adapted Regimens
45. Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2
46. The Association of Real-World CA 19-9 Level Monitoring Patterns and Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma
47. Real-world patterns of pain medication use among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).
48. Front‐line treatment patterns in multiple myeloma: An analysis of U.S.‐based electronic health records from 2011 to 2019
49. Abstract 765: Real-world serum CA19-9 level monitoring patterns and its association with clinical outcomes among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)
50. Assessing real-world survival outcomes of patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with first-line FOLFIRINOX compared to patients from a phase 1/2 trial treated with NALIRIFOX.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.